Longaeva Partners’s Spyre Therapeutics SYRE Stock Holding History
Bought
Maintained
Sold
Other funds holding SYRE
Longaeva Partners's SYRE Position: Q3 2026 in Review
Longaeva Partners opened a new position in Spyre Therapeutics (SYRE) in Q3 2026: 48,645 shares worth $4.33M. The stake represents 0.09% of the portfolio and ranks #193 among its holdings.
286 funds tracked by Wall St. Rank hold SYRE as of Q3 2026.
- Longaeva Partners held 48,645 shares of Spyre Therapeutics worth $4.33M as of Q3 2026.
- Spyre Therapeutics was a new Longaeva Partners position in Q3 2026.
- Spyre Therapeutics made up 0.09% of Longaeva Partners's portfolio in Q3 2026, its #193 holding.
- 286 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2026.
Based on Longaeva Partners's 13F filing for Q3 2026, filed 16 Nov 2026.